Immune Tolerance for Autoimmune Disease and Cell Transplantation

Annual Review of Biomedical Engineering

Volumn 18, Issue , 2016, Pages 181-205

  Luo, Xunrong ^a,b   Miller, Stephen D ^c   Shea, Lonnie D ^d  

^a Division of Nephrology and Hypertension   (United States)

^b Department of Entomology   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cell therapies; Immunomodulation; Inverse vaccines; Nanotechnology; Tolerance

Indexed keywords

ANTIGENS; CELLS; CYTOLOGY; DISEASE CONTROL; FITS AND TOLERANCES; NANOTECHNOLOGY; TISSUE;

AUTOIMMUNE DISEASE; CELL THERAPY; CELL TRANSPLANTATION; CURRENT TREATMENTS; ENABLING TECHNOLOGIES; IMMUNE TOLERANCES; IMMUNO MODULATIONS; OPPORTUNISTIC INFECTIONS;

IMMUNE SYSTEM;

NANOPARTICLE; PEPTIDE; VACCINE;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELL PROTECTION; CELL TRANSPLANTATION; CHIMERA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EX VIVO STUDY; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INTRACELLULAR SIGNALING; NANOPHARMACEUTICS; NONHUMAN; SENSITIZATION; SUPPRESSOR CELL; ANIMAL; AUTOIMMUNE DISEASES; BIOLOGICAL MODEL; EVIDENCE BASED MEDICINE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNE DISEASES; CELL TRANSPLANTATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MODELS, IMMUNOLOGICAL; TREATMENT OUTCOME;

EID: 84978977013     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-110315-020137     Document Type: Article

References (150)

1. Miller SD, Turley DM, Podojil JR. 2007. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7:665-77
2. Zakrzewski JL, van den Brink MR, Hubbell JA. 2014. Overcoming immunological barriers in regenerative medicine. Nat. Biotechnol. 32:786-94
3. Tobias LD. 2010. A Briefing Report on Autoimmune Diseases and AARDA: Past, Present, and Future. Eastpointe, MI: AARDA
4. Fischbach MA, Bluestone JA, Lim WA. 2013. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 5:179ps7
5. Shapiro AM, Lakey JR, Ryan EA, KorbuttGS, Toth E, et al. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-38
6. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, et al. 2005. Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-69
7. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, et al. 2008. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26:443-52
8. Zhang D, JiangW, Liu M, Sui X, Yin X, et al. 2009. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 19:429-38
9. Weiner HL. 2009. The challenge ofmultiple sclerosis: How do we cure a chronic heterogeneous disease? Ann. Neurol. 65:239-48
10. Hackstein H, Thomson AW. 2004. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4:24-34
11. Kobashigawa JA, Patel JK. 2006. Immunosuppression for heart transplantation:Where are we now? Nat. Clin. Pract. Cardiovasc. Med. 3:203-12
12. Van Gelder H, Charles-Schoeman C. 2014. The heart in inflammatory myopathies. Rheum. Dis. Clin. N. Am. 40:1-10
13. Nikolich-Zugich J, Slifka MK, Messaoudi I. 2004. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 4:123-32
14. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. 2005. Multiple sclerosis. Immunol. Rev. 204:208-31
15. Sulzberger MB. 1929. Experiments in prevention and in desensitization. Arch.Dermatol. Syphilol. 20:669-697
16. Chiller JM, Weigle WO. 1971. Cellular events during induction of immunologic unresponsiveness in adult mice. J. Immunol. 106:1647-53
17. Burstein HJ, Shea CM, Abbas AK. 1992. Aqueous antigens induce in vivo tolerance selectively in IL-2-and IFN-γ-producing (Th1) cells. J. Immunol. 148:3687-91
18. Critchfield JM, Racke MK, Zúniga-Pflücker JC, Cannella B, Raine CS, et al. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139-43
19. Gaur A, Wiers B,Liu A, Rothbard J, FathmanCG. 1992. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258:1491-94
20. Racke MK, Critchfield JM, Quigley L, Cannella B, Raine CS, et al. 1996. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann. Neurol. 39:46-56
21. Smith CE, Eagar TN, Strominger JL, Miller SD. 2005. Differential induction of IgE-mediated anaphylaxis after soluble versus cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. PNAS 102:9595-600
22. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, et al. 1996. Late complications of immune deviation therapy in a nonhuman primate. Science 274:2054-57
23. Kontos S, Kourtis IC, Dane KY, Hubbell JA. 2013. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. PNAS 110:e60-68
24. Griffith TS, Ferguson TA. 2011. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 35:456-66
25. Nagata S, Hanayama R, Kawane K. 2010. Autoimmunity and the clearance of dead cells. Cell 140:619-30
26. Getts DR, McCarthy DP, Miller SD. 2013. Exploiting apoptosis for therapeutic tolerance induction. J. Immunol. 191:5341-46
27. Ferguson TA, Choi J, Green DR. 2011. Armed response: how dying cells influence T-cell functions. Immunol. Rev. 241:77-88
28. Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, et al. 2008. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 181:6923-33
29. Crispe IN. 2011. Liver antigen-presenting cells. J. Hepatol. 54:357-65
30. Dunham RM, Thapa M, Velazquez VM, Elrod EJ, Denning TL, et al. 2013. Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J. Immunol. 190:2009-16
31. Burghardt S, Erhardt A, Claass B, Huber S, Adler G, et al. 2013. Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. J. Immunol. 191:5574-82
32. Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H. 2011. Hepatic stellate cells function as regulatory bystanders. J. Immunol. 186:5549-55
33. Kasagi S, Zhang P, Che L, Abbatiello B, Maruyama T, et al. 2014. In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response. Sci. Transl. Med. 6:241ra78
34. Wetzig R, Hanson DG, Miller SD, Claman HN. 1979. Binding of ovalbumin to mouse spleen cells with and without carbodiimide. J. Immunol. Methods 28:361-68
35. Podojil JR, Miller SD. 2009. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 229:337-55
36. Prasad S, Xu D, Miller SD. 2012. Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes. Rev. Diabet. Stud. 9:319-27
37. Turley DM, Miller SD. 2007. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J. Immunol. 178:2212-20
38. Karpus WJ, Peterson JD, Miller SD. 1994. Anergy in vivo: down-regulation of antigen-specific CD4+ Th1 but not Th2 cytokine responses. Int. Immunol. 6:721-30
39. Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, et al. 2011. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187:2405-17
40. Vandenbark AA, Barnes D, Finn T, Bourdette DN, Whitham R, et al. 2000. Differential susceptibility of human Th1 versus Th2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigenpresenting cells. Int. Immunol. 12:57-66
41. Vandenbark AA, Celnik B, Vainiene M, Miller SD, Offner H. 1995. Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism. J. Immunol. 155:5861-67
42. Lutterotti A, Yusef S, Sputtek A, Sturner K, Stellmann J-P, et al. 2013. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci. Transl.Med. 5:188ra75
43. Getts DR,Martin AJ, McCarthyDP, Terry RL,HunterZH, et al. 2012. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30:1217-24
44. Jing J, Yang IV, Hui L, Patel JA, Evans CM, et al. 2013. Role of macrophage receptor with collagenous structure in innate immune tolerance. J. Immunol. 190:6360-67
45. Canton J, Neculai D, Grinstein S. 2013. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13:621-34
46. Kanno S, Furuyama A, Hirano S. 2007. A murine scavenger receptor MARCO recognizes polystyrene nanoparticles. Toxicol. Sci. 97:398-406
47. Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, et al. 2014. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8:2148-60
48. Getts DR, Terry RL, Getts MT, Deffrasnes C,MüllerM, et al. 2014. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 6:219ra7
49. Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, et al. 2015. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. PNAS 112:e156-65
50. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. 2012. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. PNAS 109:11270-75
51. Carambia A, Freund B, SchwingeD, Bruns OT, Salmen SC, et al. 2015. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. J. Hepatol. 62:1349-56
52. Carambia A, Freund B, Schwinge D,Heine M, Laschtowitz A, et al. 2014. TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. J. Hepatol. 61:594-99
53. McHugh MD, Park J, Uhrich R, Gao W, Horwitz DA, Fahmy TM. 2015. Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials 59:172-81
54. Jhunjhunwala S, Chen LC, Nichols EE, Thomson AW, Raimondi G, Little SR. 2013. All-trans retinoic acid and rapamycin synergize with transforming growth factorβ1 to induce regulatory Tcells but confer different migratory capacities. J. Leukoc. Biol. 94:981-89
55. Pabst O, Mowat AM. 2012. Oral tolerance to food protein. Mucosal Immunol. 5:232-39
56. Wells HG, Osborne TB. 1911. The biological reactions of the vegetable proteins. I. Anaphylaxis. J. Infect. Dis. 8:66-124
57. Faria AMC,Weiner HL. 2005. Oral tolerance. Immunol. Rev. 206:232-59
58. MizrahiM, Ilan Y. 2009. The gut mucosa as a site for induction of regulatory T cells. Curr. Pharm. Des. 15:1191-202
59. Brandtzaeg P, KiyonoH, Pabst R, RussellMW.2008. Terminology: nomenclature ofmucosa-associated lymphoid tissue. Mucosal Immunol. 1:31-37
60. Bitar DM, Whitacre CC. 1988. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol. 112:364-70
61. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. 1991. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147:2155-63
62. Khoury SJ, HancockWW,Weiner HL. 1992. Oral tolerance tomyelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factorβ, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-64
63. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-40
64. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor βafter antigen-specific triggering. PNAS 89:421-25
65. Kennedy KJ, Smith WS, Miller SD, Karpus WJ. 1997. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. J. Immunol. 159:1036-44
66. Slavin AJ, Maron R, Weiner HL. 2001. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int. Immunol. 13:825-33
67. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. 2010. Enhancing oral vaccine potency by targeting intestinal M cells. PLOS Pathog. 6:e1001147
68. des Rieux A, Fievez V, GarinotM, Schneider YJ, Preat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116:1-27
69. Kohli N, Westerveld DR, Ayache AC, Verma A, Shil P, et al. 2014. Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. Mol. Ther. 22:535-46
70. Lee WK, Park JY, Jung S, Yang CW, Kim WU, et al. 2005. Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J. Control. Release 105:77-88
71. Kwon KC, Nityanandam R, New JS, Daniell H. 2013. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in β-TC6 cells. Plant Biotechnol. J. 11:77-86
72. Su J, Zhu L, Sherman A, Wang X, Lin S, et al. 2015. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials 70:84-93
73. Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM. 2004. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. PNAS 101:5680-85
74. Bowman K, Sarkar R, Raut S, Leong KW. 2008. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control. Release 132:252-59
75. Goldmann K, Ensminger SM, Spriewald BM. 2012. Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance. Clin. Vaccine Immunol. 19:1758-64
76. Merad M, Ginhoux F, Collin M. 2008. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8:935-47
77. Apostolou I, von Boehmer H. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199:1401-8
78. Ganguly D, Haak S, Sisirak V, Reizis B. 2013. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 13:566-77
79. Szczepanik M. 2014. Skin-induced tolerance as a new needle free therapeutic strategy. Pharmacol. Rep. 66:192-97
80. Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, et al. 2012. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int. J. Nanomedicine 7:1475-87
81. Manolova V, Flace A, BauerM, Schwarz K, Saudan P, Bachmann MF. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38:1404-13
82. Zhan X, Tran KK, Shen H. 2012. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. Mol. Pharm. 9:3442-51
83. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, et al. 2008. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359:1909-20
84. Ludvigsson J, KriskyD, Casas R, Battelino T, Castano L, et al. 2012. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366:433-42
85. Daniel C, Weigmann B, Bronson R, von Boehmer H. 2011. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J. Exp. Med. 208:1501-10
86. Northrup L, Sestak JO, Sullivan BP, Thati S, Hartwell BL, et al. 2014. Co-delivery of autoantigen and B7 pathway modulators suppresses experimental autoimmune encephalomyelitis. AAPS J. 16:1204-13
87. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, et al. 2013. Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Investig. 123:844-54
88. Clatworthy MR, Aronin CE, Mathews RJ, Morgan NY, Smith KG, Germain RN. 2014. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat. Med. 20:1458-63
89. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, et al. 2012. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 1:191-99
90. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, et al. 2010. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 207:681-88
91. Waithman J, Allan RS, Kosaka H, Azukizawa H, Shortman K, et al. 2007. Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. J. Immunol. 179:4535-41
92. Engman C, Wen Y, Meng WS, Bottino R, Trucco M, Giannoukakis N. 2015. Generation of antigenspecific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation. Clin. Immunol. 160:103-23
93. Cappellano G, Woldetsadik AD, Orilieri E, Shivakumar Y, Rizzi M, et al. 2014. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine 32:5681-89
94. Lewis JS, Dolgova NV, Zhang Y, Xia CQ, Wasserfall CH, et al. 2015. A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabeticNODmice. Clin. Immunol. 160:90-102
95. Yoon YM, Lewis JS, CarstensMR, Campbell-Thompson M, Wasserfall CH, et al. 2015. A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci. Rep. 5:13155
96. Glowacki AJ, Gottardi R, Yoshizawa S, Cavalla F, Garlet GP, et al. 2015. Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease. Ann. Biomed. Eng. 43:593-602
97. Alegre ML, Florquin S, Goldman M. 2007. Cellular mechanisms underlying acute graft rejection: time for reassessment. Curr. Opin. Immunol. 19:563-68
98. Mellor AL, Munn DH. 2008. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8:74-80
99. Glotz D, Tambur A. 2015. Stratifying patients based on epitope mismatching: ready for primetime? Am. J. Transplant. 15:2021-22
100. Spierings E. 2014. Minor histocompatibility antigens: past, present, and future. Tissue Antigens 84:374-60
101. Cobbold S,Waldmann H. 1998. Infectious tolerance. Curr. Opin. Immunol. 10:518-24
102. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F,Mfarrej B, et al. 2008. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J. Exp. Med. 205:3133-44
103. Jordan SC, Choi J, Vo A. 2015. Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 7:377-98
104. Poggio ED, Clemente M, Hricik DE, Heeger PS. 2006. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J. Am. Soc. Nephrol. 17:564-72
105. Lúcia M, Luque S, Crespo E, Melilli E, Cruzado JM, et al. 2015. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney Int. 88:874-87
106. Scandling JD, Busque S, Dejbakhsh-Jones S, BenikeC,Millan MT, et al. 2008. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358:362-68
107. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, et al. 2008. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358:353-61
108. Leventhal J, AbecassisM,Miller J, Gallon L, Ravindra K, et al. 2012. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4:124ra28
109. Leventhal J, Abecassis M, Miller J, Gallon L, Tollerud D, et al. 2013. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 95:169-76
110. Leventhal JR,Mathew JM, Salomon DR, Kurian SM, SuthanthiranM, et al. 2013. Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J. Am. Soc. Nephrol. 24:1376-85
111. Talawila N, Pengel LH. 2015. Does belatacept improve outcomes for kidney transplant recipients? A systematic review. Transpl. Int. 28:1251-64
112. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I. 2008. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 86:10-15
113. Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, et al. 2007. Dendritic cells with TGF-β1 differentiate naive CD4+CD25-T cells into islet-protective Foxp3+ regulatory T cells. PNAS 104:2821-26
114. Pothoven KL, Kheradmand T, Yang Q, Houlihan JL, Zhang H, et al. 2010. Rapamycin-conditioned donor dendritic cells differentiateCD4CD25Foxp3Tcells in vitrowithTGF-β1 for islet transplantation. Am. J. Transplant. 10:1774-84
115. Wood KJ, Sakaguchi S. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3:199-210
116. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. 2014. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am. J. Transplant. 14:750-63
117. Tan J, Wu W, Xu X, Liao L, Zheng F, et al. 2012. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307:1169-77
118. Luan Y, Mosheir E, Menon MC, Wilson D, Woytovich C, et al. 2013. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4+ Foxp3+ Treg expansion. Am. J. Transplant. 13:3123-31
119. Ochando J, Conde P, Bronte V. 2015. Monocyte-derived suppressor cells in transplantation. Curr. Transplant. Rep. 2:176-83
120. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, et al. 2015. Immunity 42:1143-58
121. Bryant J, LerretNM, Wang JJ, KangHK, Tasch J, et al. 2014. Preemptive donor apoptotic cell infusions induce IFN-γ-producing myeloid-derived suppressor cells for cardiac allograft protection. J. Immunol. 192:6092-101
122. Gibly RF, Graham JG, Luo X, LoweWL Jr, Hering BJ, Shea LD. 2011. Advancing islet transplantation: from engraftment to the immune response. Diabetologia 54:2494-505
123. Forrester JV, Xu H, Lambe T, Cornall R. 2008. Immune privilege or privileged immunity? Mucosal Immunol. 1:372-81
124. Dumont CM, Park J, Shea LD. 2015. Controlled release strategies for modulating immune responses to promote tissue regeneration. J. Control. Release 219:155-56
125. Hlavaty KA, Gibly RF, Zhang X, Rives CB, Graham JG, et al. 2014. Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds. Am. J. Transplant. 14:1523-32
126. Liu JMH, Zhang J, Zhang X,Hlavaty KA, Ricci CF, et al. 2015. Transforming growth factorβ1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets. Biomaterials 80:11-19
127. Chen T, Yuan J, Duncanson S, Hibert ML, Kodish BC, et al. 2015. Alginate encapsulant incorporating CXCL12 supports long-term allo-and xenoislet transplantation without systemic immune suppression. Am. J. Transplant. 15:618-27
128. Bischoff L, Alvarez S, Dai DL, Soukhatcheva G, Orban PC, Verchere CB. 2015. Cellular mechanisms of CCL22-mediated attenuation of autoimmune diabetes. J. Immunol. 194:3054-64
129. Graham JG, Zhang X,Goodman A, Pothoven K, Houlihan J, et al. 2013.PLG scaffold delivered antigenspecific regulatory T cells induce systemic tolerance in autoimmune diabetes. Tissue Eng. A 19:1465-75
130. LauHT, Yu M, Fontana A, Stoeckert CJ Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109-12
131. Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, Askenasy N. 2007. Pancreatic islets under attack: cellular and molecular effectors. Curr. Pharm. Des. 13:749-60
132. Plenter RJ, Grazia TJ, Nelson DP, Zamora MR, Gill RG, Pietra BA. 2015. Ectopic expression of Fas ligand on cardiomyocytes renders cardiac allografts resistant to CD4+ T-cell mediated rejection. Cell Immunol. 293:30-33
133. Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, et al. 2011. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J. Immunol. 187:5901-9
134. Hume PS, Anseth KS. 2010. Inducing local T cell apoptosis with anti-Fas-functionalized polymeric coatings fabricated via surface-initiated photopolymerizations. Biomaterials 31:3166-74
135. Chen JJ, Sun Y, Nabel GJ. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714-17
136. Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17:795-808
137. LuoX,Pothoven KL,McCarthyD,DeGutesM,Martin A, et al. 2008. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. PNAS 105:14527-32
138. Wang S, Tasch J,KheradmandT,Ulaszek J, Ely S, et al. 2013. Transient B-cell depletion combined with apoptotic donor splenocytes induces xeno-specific T-and B-cell tolerance to islet xenografts. Diabetes 62:3143-50
139. LuoX,Pothoven KL,McCarthyD,DeGutesM,Martin A, et al. 2008. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. PNAS 105:14527-32
140. Wang S, Zhang X, Zhang L, Bryant J, Kheradmand T, et al. 2014. Preemptive tolerogenic delivery of donor antigens for permanent allogeneic islet graft protection. Cell Transplant. 24:1155-65
141. Eagar TN, Karandikar NJ, Bluestone J, Miller SD. 2002. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur. J. Immnol. 32:972-81
142. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, et al. 2007. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J. Immunol. 179:5204-10
143. Kheradmand T, Wang S, Bryant J, Tasch JJ, Lerret N, et al. 2012. Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J. Immunol. 189:804-12
144. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303-7
145. Chen G, Kheradmand T, Bryant J, Wang S, Tasch J, et al. 2012. Intragraft CD11b+IDO+ cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. Am. J. Transplant. 12:2920-29
146. Bryant J, Hlavaty KA, Zhang X, Yap WT, Zhang L, et al. 2014. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 35:8887-94
147. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, et al. 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289-302
148. Huang L, Lemos HP, Li L, Li M, Chandler PR, et al. 2012. Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J. Immunol. 188:4913-20
149. Peterson JC, Nordstrom RJ, Long RK. 1976. Subtle source of contamination in spectrophones. Appl. Opt. 15:2974-76
150. Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. 2011. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 32:3094-105